A definitive resource for pharmacy directors, VPs of Pharmacy, CFOs, and health system supply chain leaders navigating rising drug costs, GPO compliance, purchasing analytics, and the emerging opportunity to align reimbursement data with procurement decisions.
Why Drug Purchasing Optimization Matters Right Now
Hospital pharmacy has quietly become one of the most important financial functions in the health system. Drug purchasing is no longer just a procurement exercise. It is a margin protection strategy, a revenue opportunity, and increasingly, a competitive differentiator.
The numbers tell the story clearly. According to the American Society of Health-System Pharmacists (ASHP), U.S. prescription drug spending surged 12.7% in 2025 to $915.2 billion, one of the fastest growth rates in two decades. In 2026, overall drug spending is projected to exceed $1 trillion for the first time, with hospital and clinic drug expenditures expected to rise an additional 4-6% and 14-16% respectively. At the hospital level, drug costs now represent nearly 10% of total operating expenses, making pharmaceuticals one of the fastest-growing line items in the cost structure.
These aren’t short-term fluctuations. Specialty drugs, cancer biologics, biosimilars, GLP-1 therapies, and infused medications are permanently reshaping the cost profile of hospital pharmacy. GLP-1 drugs alone (tirzepatide and semaglutide) accounted for over $131 billion in 2025 spending, representing 14% of the entire U.S. drug market. As these therapies migrate from clinics into inpatient and outpatient hospital settings, every decision a pharmacy purchasing team makes carries escalating financial weight.
At the same time, 77% of hospital pharmacy teams are actively focused on reducing drug costs, and 63% of pharmacy leaders report being assigned specific savings targets, according to Bluesight’s 2025 Hospital Pharmacy Purchasing Trends Report. Yet 88% of hospitals are simultaneously dealing with pharmacy technician shortages, limiting their capacity to manually analyze purchasing options and execute savings strategies at scale.
The result is a structural tension: rising financial pressure, shrinking staff capacity, and an expanding set of purchasing decisions that require data, speed, and precision to get right.
This post is designed to help pharmacy leaders, CFOs, and supply chain teams understand every major lever available to control drug costs, from GPO contract compliance and invoice auditing to the latest purchasing technology platforms and the emerging opportunity to align purchasing decisions with reimbursement data. Whether you are building a pharmacy cost containment program from scratch or optimizing an existing one, this is the most complete resource available on the topic.
How Hospitals Reduce Drug Costs: The Core Levers
The question “how do hospitals reduce drug costs?” doesn’t have a single answer. The most effective pharmacy cost containment programs address multiple layers simultaneously, from the unit price of each drug to how purchasing workflows are structured across the organization.
At a fundamental level, drug costs are a function of three variables: what you pay per unit, how many units you use, and how efficiently your purchasing process captures every available savings opportunity. Most hospital pharmacy budget management programs focus almost exclusively on the first variable: unit price. Best-in-class programs address all three.
Contracted Pricing and Off-Contract Leakage
The most immediate and recoverable source of pharmacy cost savings for most hospitals is closing the gap between what they are contracted to pay and what they are actually paying. Hospitals typically have access to GPO pricing, wholesaler contracts, facility-specific manufacturer agreements, and 340B pricing. The problem is that each of these pricing tiers must be correctly loaded into the ordering system, validated against invoices, and monitored continuously for drift.
Contract leakage (the difference between contracted price and actual invoice price) accumulates invisibly in most hospitals. Without automated monitoring, overcharges can persist for months or years before a manual audit surfaces them. For large health systems purchasing thousands of NDCs across dozens of suppliers, the scale of this leakage can easily reach six or seven figures annually.
Formulary and NDC Optimization
A second major lever is identifying where lower-cost clinically equivalent alternatives exist and systematically converting purchasing to those alternatives. This includes generic substitution, biosimilar adoption, and switching between equivalent NDCs from different manufacturers at materially different price points.
This is not simply about choosing the cheapest option. It requires understanding clinical equivalence, shortage risk, contract tier implications, and increasingly reimbursement impact. A drug that saves $50 on acquisition cost but generates $2,000 less in Medicare reimbursement is not a savings opportunity; it is a financial liability in disguise. (More on this in subsequent sections.)
Utilization Management
Utilization management (ensuring that medications are prescribed, administered, and dispensed in clinically appropriate quantities) is the lever most closely tied to clinical pharmacy programs like antimicrobial stewardship, IV-to-PO conversion, and dose optimization. While this falls partly outside the purchasing team’s direct control, the financial impact of utilization programs can exceed that of price reduction initiatives in high-acuity settings.
Inventory Discipline
Carrying excess inventory, over-ordering against periodic automatic replacement (PAR) levels, and allowing medications to expire represent direct costs that never appear on an invoice. Disciplined pharmacy inventory management, including standardized PAR levels, routine cycle counts, and centralized visibility across sites, is one of the fastest ways to recover dollars that are being wasted.
How Much Can Hospitals Save?
The savings available through a disciplined, data-driven pharmacy cost containment program vary significantly by organization size, current program maturity, and drug mix. However, benchmarks from technology-enabled programs suggest that hospitals actively using purchasing analytics and optimization tools consistently capture hundreds of thousands to millions of dollars annually in medication spend reduction, often within the first year of implementation.
GPO Contracts and Compliance: Maximizing Your Group Purchasing Advantage
Group Purchasing Organizations (GPOs) are the backbone of pharmaceutical procurement for most U.S. hospitals. By aggregating purchasing volume across hundreds or thousands of member facilities, GPOs negotiate pricing agreements with manufacturers and distributors that individual hospitals could rarely achieve on their own.
Nearly every hospital in the United States is a GPO member. The challenge isn’t access to GPO contracts, it’s ensuring that those contracts are actually being used correctly, consistently, and completely.
How GPO Pricing Works
GPO contracts establish tiered pricing based on market share commitments, volume thresholds, and product category agreements. The pricing is loaded into a drug wholesaler’s ordering system and applied automatically… in theory. In practice, contract misloads, pricing updates, and system integration failures create persistent gaps between the price a hospital is supposed to pay and what appears on their invoice.
There are three primary purchasing channels through which hospitals access discounted pharmaceutical pricing:
GPO contracts establish aggregate pricing across the member network and typically offer the best pricing on high-volume generic and brand medications.
Facility-specific contracts are direct agreements between a manufacturer and an individual hospital or health system, often negotiated when a facility’s volume exceeds GPO thresholds or where the facility has differentiated purchasing patterns.
Wholesaler own-use contracts are pricing agreements tied to a hospital’s primary wholesale distributor relationship and can supplement GPO pricing for specific categories.
The GPO Compliance Problem
Off-contract purchasing is one of the most significant and underappreciated sources of pharmacy cost leakage. When purchasing teams order a product outside the contracted channel – whether due to stockouts, manual error, system misloads, or simple inertia – they forfeit the contracted discount and pay a higher price, often without any visibility into the deviation.
According to Bluesight’s purchasing trends data, GPO compliance failures represent a material budget exposure for most hospitals. Monitoring compliance at the line-item level – across every NDC, every order, every invoice – is not possible manually for teams managing 20,000 or more NDCs. This is where technology becomes essential.
Maximizing Savings Available from GPO Relationships
Best practices for maximizing GPO contract value include:
- Ensuring all active contracts are correctly loaded in the wholesaler ordering system and validated quarterly
- Monitoring purchasing compliance at the NDC level and generating exception reports for off-contract orders
- Evaluating GPO tier eligibility regularly — as hospital volume grows, tier upgrades may be available that reduce unit cost
- Coordinating with the GPO on failure-to-supply credits when contracted products are unavailable due to manufacturer shortage
- Aligning 340B purchasing with GPO strategy to ensure the organization is using the most advantageous pricing channel for each eligible drug
- Assessing whether direct manufacturer contracts would outperform GPO pricing for specific high-spend categories
GPO vs. Direct Manufacturer Contracts: Which Is Better?
The answer is: it depends on volume, category, and negotiating leverage. GPOs offer simplicity and breadth. A single membership provides access to contracts across thousands of products. Direct manufacturer contracts can provide deeper discounts on specific drugs where a hospital’s volume justifies negotiation, but they require administrative overhead to maintain and monitor.
Most sophisticated pharmacy purchasing programs use both, with the primary GPO relationship providing baseline coverage and direct contracts supplementing where volume supports it.
Invoice and Pricing Accuracy: The Hidden Drain on Pharmacy Budgets
Pharmacy invoice errors are more common, more costly, and harder to detect than most pharmacy leaders realize. Even when a hospital has correctly negotiated contracts and the right pricing loaded into its systems, the actual invoices received from wholesalers and manufacturers do not always reflect contracted pricing.
The sources of invoice discrepancies include:
- Contract misloads: Pricing is not correctly loaded or updated in the wholesaler’s system
- Pricing update lag: Manufacturer price changes, contract tier transitions, and GPO updates can take weeks to propagate through ordering systems
- Product substitution errors: When an ordered product is substituted by the wholesaler, the substituted product may carry different pricing
- Chargebacks and credits not applied: Manufacturer rebates, failure-to-supply credits, and chargeback adjustments may not be reflected in invoices
- 340B pricing errors: 340B-eligible purchases that are not correctly flagged and priced can result in paying commercial prices for drugs that should carry 340B discounts
Each of these discrepancies may appear small in isolation: just a few dollars per unit on a single order. But across thousands of orders per month, the aggregate impact can exceed $100,000 per year for a mid-size hospital and substantially more for large health systems.
Why Manual Invoice Auditing Doesn’t Scale
Traditional invoice auditing requires someone to manually compare purchase order pricing to invoice pricing to contracted pricing – line by line, NDC by NDC. For a hospital purchasing team managing 20,000+ NDCs across multiple suppliers, this is not feasible at any meaningful frequency. Manual audits typically happen quarterly at best, which means months of overcharges can accumulate before they are identified.
Automated pharmacy invoice auditing tools solve this problem by continuously comparing every invoice against contracted pricing and flagging discrepancies in real time. According to Bluesight’s CostCheck platform data, each overcharge flag helps hospitals avoid overpayments that can exceed $100,000, while systematic invoice monitoring tracks every opportunity from review through resolution – including credits, rebills, and total savings captured.
Building a Pharmacy Invoice Audit Program
Whether using manual processes or automated tools, an effective invoice audit program should:
- Define the comparison baseline: Which price is “correct” – GPO contracted price, facility contract price, or wholesaler pricing? Clear hierarchy rules prevent ambiguity
- Establish a review cadence: Automated tools enable continuous monitoring; manual programs should target weekly or bi-weekly review cycles
- Track recovery: Credits and rebills should be tracked to closure, not just flagged. Many hospitals identify discrepancies but never follow through to recover the overpayment
- Report to leadership: Invoice accuracy data should be part of regular pharmacy financial reporting so leadership understands both the scope of the problem and the savings being recovered
NDC Optimization and Lower-Cost Alternatives
One of the highest-yield areas in pharmacy cost optimization is systematically identifying where lower-cost, clinically equivalent drug alternatives exist and converting purchasing to those alternatives. This process operates at the National Drug Code (NDC) level: the specific product and package size identifier that determines exactly what was purchased and at what price.
NDC optimization encompasses several distinct strategies:
Generic Drug Substitution
When a brand-name drug loses patent protection, generic versions typically enter the market at 70–90% lower cost. But generic adoption isn’t automatic. It requires formulary updates, system configuration, staff communication, and active monitoring to ensure purchasing shifts to the generic product.
Demand matching with the wholesaler (coordinating timing so that sufficient generic inventory is available at the point of patent expiration) is an important tactical step that many hospitals underinvest in. Without it, purchasing can default to the brand product simply due to availability, even after the generic is approved and priced.
Biosimilar Adoption
Biosimilars represent one of the largest cost reduction opportunities in hospital pharmacy today, particularly for oncology, immunology, and specialty drug categories. According to ASHP, biosimilar adoption increased meaningfully in 2025, especially in oncology, though adoption continues to vary by drug, site of care, and contracting dynamics.
The clinical and financial case for biosimilar adoption is strong. However, pharmacy leaders should be aware that biosimilar purchasing decisions carry additional complexity:
- Multiple biosimilars may be available for a single reference biologic, each at different price points
- GPO and direct manufacturer contracts for biosimilars can vary significantly in structure and terms
- For Medicare Part B drugs, biosimilar purchasing decisions have direct reimbursement implications that must be factored into the analysis (see revenue optimization section below)
- Payer formulary coverage for biosimilars varies, which can affect both administration workflow and reimbursement
Lower-Cost NDC Identification Within the Same Drug Category
Even for drugs that are not subject to generic substitution, meaningful price variation often exists between equivalent NDCs from different manufacturers. The same molecule, same dose form, same clinical equivalence… but different acquisition costs from different suppliers.
Pharmacy purchasing analytics platforms identify these opportunities systematically, comparing pricing across available NDCs and quantifying the per-unit and annualized savings available from switching. Bluesight’s CostCheck platform reports an average savings of up to $15,000 per recommendation from NDC-level optimization.
Package Size Optimization
Drug acquisition cost is also affected by package size selection. A product available in a 10-unit vial and a 25-unit vial may carry different per-unit pricing. For drugs with stable consumption patterns, optimizing toward the most cost-efficient package size can generate incremental savings with minimal workflow impact.
The Biosimilar Margin Calculation: A Critical Consideration
Not all lower-cost NDC alternatives are straightforward savings opportunities when the drug is eligible for Medicare Part B reimbursement. The difference between acquisition cost and reimbursement (the margin) can vary dramatically between biosimilars and reference biologics. Pharmacy purchasing teams that optimize solely on acquisition cost without considering reimbursement may inadvertently reduce margin, not improve it.
This is one of the most important evolving dimensions of pharmacy purchasing optimization: the shift from cost-only analysis to fully margin-aware purchasing decisions.
Pharmacy Purchasing Technology: A Buyer’s Guide
Pharmacy purchasing technology has evolved from basic order management into a sophisticated category of specialized analytics and optimization platforms. For pharmacy leaders evaluating solutions, the market has become meaningfully differentiated, and choosing the right platform has direct implications for how much savings your program can capture and how efficiently your team can operate.
The Technology Stack for Hospital Pharmacy Purchasing
Hospital pharmacy purchasing operates across several interconnected technology layers:
Pharmacy Information Systems (PIS) like Epic Willow, Meditech, and Cerner Millennium manage medication dispensing, clinical decision support, and workflow. These systems are not designed for cost optimization. They manage drug administration and clinical records, not purchasing economics.
Wholesaler Ordering Platforms like McKesson Connect and Cencora/AmerisourceBergen’s order management tools provide the transaction layer through which most purchases occur. These platforms facilitate ordering and provide basic transaction history but offer limited analytics for cost optimization.
ERP and Supply Chain Systems like Oracle, SAP, and Workday provide enterprise procurement governance across categories but lack the pharmacy-specific intelligence needed to evaluate contract compliance, NDC alternatives, and shortage risk at the drug level.
Pharmacy Cost Optimization Platforms are the purpose-built layer that most hospitals are missing. These platforms sit above the transaction layer, ingesting purchasing data from the wholesaler and ERP, comparing it against contract databases, and surfacing actionable savings opportunities. This is the category where the most meaningful innovation is happening and where the ROI case is clearest.
What to Look For in Pharmacy Purchasing Optimization Software
When evaluating pharmacy purchasing analytics and optimization platforms, the following criteria should guide the assessment:
- Data Specificity: The most important differentiator between platforms is whether they work with your organization’s actual purchasing data or generate recommendations based on aggregated market averages. A platform that says “you could save X if you switched to generic Y” based on population-level data is fundamentally less useful than one that analyzes your actual invoices, your specific contracts, your NDC purchasing history, and your GPO tier status. Always ask: “Are your recommendations based on my data, or market benchmarks?”
- GPO Contract Integration: The platform should have direct visibility into your contracted pricing across your GPO relationships and facility-specific agreements. Without this, the platform cannot accurately quantify the gap between contracted price and actual invoice price.
- Invoice Audit Capability: Automated comparison of every invoice against contracted pricing, with real-time flagging of discrepancies, is a core function. Ask about how credits and recoveries are tracked to closure.
- NDC-Level Recommendations: Savings recommendations should be at the NDC level, not just the drug category level, and should include clinical equivalence verification, shortage risk assessment, and quantified financial impact per recommendation.
- GPO Compliance Monitoring: The platform should provide line-item visibility into GPO compliance status for every purchase, not just aggregate compliance rates.
- Shortage Risk Integration: Given the material financial and operational impact of drug shortages, leading platforms integrate shortage risk data alongside cost optimization recommendations so teams can evaluate savings opportunities with visibility into supply stability.
- Time Investment Required: Pharmacy teams are capacity-constrained. A platform that requires 10+ hours per week of staff time to generate value is not sustainable. Leading platforms are designed for 30–60 minutes per week of active management, with the heavy analytical work done by the platform itself.
- Vendor Pharmacy Expertise: Technology built by engineers without deep pharmacy operational knowledge tends to produce recommendations that look right on paper but create workflow friction in practice. Evaluate the vendor’s pharmacy background, not just their technology.
- Outcomes Guarantee: Some vendors offer risk-share models that tie their compensation to documented savings. This aligns incentives and reflects genuine confidence in the platform’s ability to generate value.
A Pharmacy Purchasing Technology Platform
Bluesight’s CostCheck is a pharmacy cost optimization platform used by more than 500 hospitals. CostCheck ingests purchasing data from wholesalers and GPO databases, compares it against contracted pricing, and surfaces prioritized recommendations for invoice discrepancy resolution, NDC optimization, biosimilar conversion, and GPO compliance improvement. The platform requires approximately 30 minutes per week of staff time and has generated over $100 million in documented savings across its customer base. CostCheck is notable for its integration with ShortageCheck (Bluesight’s shortage intelligence platform), which allows teams to evaluate savings opportunities with real-time shortage risk visibility, and for its Medicare Margin Optimizer, which layers Part B reimbursement data into purchasing recommendations for specialty and infused medications.
Pharmacy Purchasing Software for Small and Critical Access Hospitals
Smaller hospitals and critical access facilities often assume that pharmacy purchasing optimization technology is only viable for large health systems. This assumption is incorrect and costly. The economics of purchasing optimization scale with drug spend, not facility size. A critical access hospital spending $5 million annually on medications has the same types of contract leakage, invoice discrepancies, and NDC optimization opportunities as a 500-bed academic medical center, proportionally to their spend.
Many leading platforms are designed to work with lean pharmacy teams and limited staff time, making them viable for facilities of all sizes. The case study from Marshall Medical, a small rural hospital that used purchasing analytics to identify meaningful drug savings with minimal staff time, is representative of what small facilities can achieve with the right technology.
AI and Pharmacy Purchasing Optimization
Artificial intelligence and machine learning are beginning to play a meaningful role in pharmacy purchasing, particularly in three areas:
- Demand forecasting: AI models can predict drug consumption patterns more accurately than PAR-based inventory systems, reducing both stockouts and excess carrying costs.
- Anomaly detection: Machine learning can identify unusual patterns in purchasing data that may indicate contract leakage, pricing errors, or off-contract buying.
- Shortage prediction: AI-powered platforms can provide early warning of potential drug shortages by monitoring supply chain signals, regulatory filings, and manufacturer communications before shortages appear on official ASHP or FDA lists.
According to a 2026 survey by Tecsys, 15% of hospital pharmacy teams report having fully deployed AI or machine learning for demand forecasting, inventory optimization, or shortage prediction, with 35% in pilot or limited rollout. Adoption is accelerating, and pharmacy leaders who build the data infrastructure for AI-powered optimization today will have a meaningful competitive advantage as these capabilities mature.
Building the Business Case for Pharmacy Purchasing Technology
For pharmacy directors and CFOs evaluating purchasing technology, the ROI case is typically straightforward. Documented savings from invoice auditing, GPO compliance improvement, and NDC optimization at most hospitals exceed the cost of a specialized analytics platform within the first year.
The variables that most affect ROI include:
- Annual drug spend (higher spend = more recoverable savings)
- Current program maturity (organizations with less structured purchasing programs typically see faster, larger initial returns)
- Drug mix (higher proportion of specialty, infused, and biosimilar medications = more optimization opportunity)
- Staffing constraints (platforms that require less staff time deliver higher net value in capacity-constrained environments)
When building a business case, request a preliminary savings analysis from vendors based on your actual purchasing data. Reputable platforms can provide a credible estimate of recoverable savings before any contract is signed.
From Cost Center to Revenue Generator: Aligning Purchasing and Reimbursement Data
This section addresses the most significant emerging opportunity in hospital pharmacy finance, and one that the vast majority of pharmacy purchasing programs have yet to capture.
For decades, the pharmacy purchasing workflow has been designed to answer one question: what is the lowest acquisition cost for this drug? That framing made sense when pharmacy was primarily a cost center and when most medications were generic oral drugs purchased at commodity prices.
It no longer reflects the reality of modern hospital pharmacy.
The Structural Problem: Purchasing and Reimbursement Data Are Siloed
As specialty and infused therapies have grown as a share of the hospital formulary, a growing proportion of the medications a hospital pharmacy purchases are also sources of reimbursement revenue, particularly for drugs administered to Medicare and commercially insured patients in outpatient settings under the medical benefit (i.e., “buy and bill” drugs under Medicare Part B).
Under the buy-and-bill model, a hospital purchases a drug, administers it to a patient, and then bills Medicare or a commercial payer for both the drug and the administration. The reimbursement rate (what the payer pays) is determined by the drug’s J-code and the applicable reimbursement formula (for Medicare Part B, generally Average Sales Price plus 6%). The margin the hospital realizes is the difference between reimbursement and acquisition cost.
Here is the critical implication: two therapeutically equivalent drugs can carry dramatically different margins. The biosimilar may cost $800 less to acquire than the reference biologic, but if the reference biologic generates $1,500 more in Medicare reimbursement per vial, the “cheaper” drug is actually $700 less profitable per dose.
This dynamic is invisible in a purchasing workflow designed only to minimize acquisition cost.
The Scale of the Opportunity
According to data from Bluesight’s Margin Optimizer, two comparable specialty drugs can differ by $2,000 or more per vial in Medicare margin. At the scale of a specialty pharmacy program administering hundreds or thousands of doses per year, the financial impact of systematically unoptimized purchasing decisions, even when those decisions appear cost-efficient, can reach millions of dollars in unrealized margin.
As research highlights, charge capture errors, missed biosimilar conversions, and preventable revenue misalignments are costing health systems millions annually, and CFOs are beginning to establish pharmacy revenue integrity functions to address the problem.
What Margin-Aware Purchasing Looks Like
A margin-aware pharmacy purchasing workflow does not abandon cost optimization. It adds a second dimension to the analysis. For every purchasing recommendation involving a specialty, infused, or Medicare Part B-reimbursable drug, the purchasing team can see:
- Cost impact: How much does this change my acquisition cost?
- Revenue impact: How does this change my expected reimbursement for this drug?
- Net margin impact: What is the combined financial effect on the health system’s bottom line?
When these three data points are visible side-by-side at the point of the purchasing decision, pharmacy teams can identify three types of opportunities:
- Pure cost savings: Switches that reduce acquisition cost with neutral reimbursement impact
- Pure revenue opportunities: Changes that improve reimbursement without altering acquisition cost
- “Double wins”: Switches that simultaneously reduce acquisition cost and increase reimbursement – the most valuable opportunities in the portfolio
Bluesight’s Margin Optimizer has operationalized this framework, grouping biosimilars and reference biologics for cross-product margin comparison and making per-vial margin differences visible in the purchasing workflow for the first time.
The Coming Shift to Claims-Based Revenue Optimization
The Margin Optimizer represents the first phase of what will become a much richer analytics capability. Using Medicare average reimbursement data provides directional guidance: it tells you what a drug typically reimburses for Medicare patients. But it doesn’t account for your specific payer mix, your actual contract rates with commercial payers, or the specific claims history for your patient population.
The next phase – claims-based revenue optimization – connects a hospital’s own claims data to the purchasing workflow, enabling exact, payer-level profit calculations for every purchasing decision. Instead of “this drug typically generates approximately X in Medicare margin,” the system can tell you: “for your specific patient population and payer mix, this drug generates exactly Y in realized margin per dose.”
This capability is in development, with Bluesight planning claims data integration for CostCheck in 2026. When it arrives, it will complete the transformation of pharmacy purchasing from a cost reduction function into a comprehensive financial optimization discipline.
What This Means for Pharmacy’s Role in Health System Strategy
Forward-looking health systems are already recognizing this shift. As Visante’s Top Ten Forces Shaping Health System Pharmacy notes, pharmacy is no longer just a clinical service or cost center; it is central to enterprise growth, revenue strategy, and long-term financial sustainability. Leaders who bring pharmacy into enterprise financial decision-making alongside finance, ambulatory, and payer strategy are unlocking system-level growth that peers are missing.
For pharmacy directors, this shift represents both an opportunity and an obligation: an opportunity to demonstrate pharmacy’s strategic financial value at the executive level, and an obligation to ensure that purchasing decisions are being made with full visibility into their financial implications for the health system.
Drug Shortages and Purchasing Risk: Managing Supply Continuity Without Sacrificing Savings
Drug shortages represent one of the most disruptive and costly challenges facing hospital pharmacy purchasing today. The scale of the problem is extraordinary: according to Vizient’s 2025 survey, hospitals across the U.S. spent approximately 20 million hours managing drug shortages in 2024, translating to nearly $900 million in annual labor costs, more than double the $359 million reported in Vizient’s 2019 survey.
The average pharmacy staff time spent managing shortages has doubled from 10.5 hours per week per facility in 2019 to 24.2 hours per week in 2024. And this figure does not capture the additional costs of direct purchases outside traditional distribution channels, alternative therapy sourcing, cancelled procedures, or the downstream clinical impact of suboptimal substitutions.
The Current Shortage Landscape
Active drug shortages reached a record high of 323 in Q1 2024, according to ASHP. As of mid-2025, that number had lowered to approximately 253 active shortages, still significantly higher than the 187 recorded in 2021, and with 50% of active shortages having persisted for two or more years.
Generic drugs represent approximately 83% of all shortage activity, driven by the economics of generic pharmaceutical manufacturing: thin margins, global supply chain concentration, and limited incentives for manufacturers to maintain excess production capacity. Sterile injectables – IV antibiotics, oncology agents, electrolytes – are disproportionately affected due to the complexity of their manufacturing and the limited number of qualified production facilities globally.
The financial impact extends beyond labor. When a shortage forces a switch to an alternative product, the alternative is often more expensive, may be purchased outside the hospital’s primary distribution channel at higher prices, and may carry different reimbursement characteristics that affect margin.
The Intersection of Shortages and Purchasing Optimization
Here is the tension that drug shortages create for purchasing optimization programs: the lower-cost NDC alternative that looks like a savings opportunity today may be the drug that goes on shortage next month. Without shortage risk data integrated into the purchasing recommendation, teams can act on cost-optimization guidance that inadvertently creates supply continuity risk.
Leading pharmacy purchasing platforms address this by integrating real-time and predictive shortage intelligence directly into the savings recommendation workflow. Bluesight’s integration of ShortageCheck into CostCheck is an example of this approach: each NDC optimization recommendation includes shortage risk indicators that flag low, medium, or high supply risk, with predictive intelligence that provides up to 90 days of advance warning before a shortage appears on ASHP or FDA official lists (averaging 52 days ahead of public listing).
This integration allows purchasing teams to evaluate savings opportunities not just on cost, but on the full risk profile of the switching decision – balancing financial optimization with supply chain stability.
Best Practices for Shortage Risk Management in Purchasing
- Maintain secondary supplier relationships: Don’t rely exclusively on the primary wholesaler for high-risk drug categories. Develop pre-qualified relationships with secondary distributors and 503B outsourcing facilities before shortages hit
- Build shortage early warning into purchasing workflows: If your purchasing analytics platform doesn’t include shortage risk data, establish a separate monitoring process using ASHP and FDA shortage databases, with alert protocols for high-priority drugs
- Identify clinical alternatives proactively: For drugs with high shortage risk profiles, work with clinical pharmacy to pre-approve therapeutic alternatives before a shortage occurs, reducing the time-to-resolution when supply disruptions happen
- Coordinate demand matching on generic conversions: When planning a switch to a generic or biosimilar, work with the wholesaler to ensure sufficient inventory is available at the point of conversion
- Quantify shortage costs for leadership reporting: The labor cost, emergency purchasing premium, and clinical impact of shortages should be part of regular pharmacy financial reporting. Visibility into the true cost of shortages supports investment in technology and processes that reduce exposure
Pharmacy Purchasing Best Practices and KPIs
Pharmacy purchasing excellence doesn’t happen by accident. It requires disciplined processes, clear accountability, the right technology, and meaningful metrics that connect purchasing performance to organizational financial outcomes.
Foundational Best Practices
Start with accurate data. The foundation of every pharmacy cost optimization initiative is confidence in inventory and pricing data. Without accurate real-time inventory data, purchasing decisions are made on assumptions. Without verified contracted pricing in the ordering system, compliance monitoring is meaningless. Before investing in advanced analytics, ensure that the underlying data infrastructure is solid.
Build a structured review cadence. Cost optimization opportunities emerge continuously: new contract pricing, new NDC alternatives, new shortage risks. The best pharmacy purchasing programs establish a weekly review workflow where a pharmacist or purchasing analyst reviews the top recommendations from the analytics platform, approves actions, and tracks outcomes. Leading platforms are designed to support this workflow in 30-60 minutes per week.
Close the loop on savings. Identifying a savings opportunity is not the same as capturing it. Every recommendation, whether an invoice discrepancy, an NDC switch, or a GPO compliance issue, should have a defined resolution workflow, a responsible owner, and tracked outcomes. Programs that identify but don’t resolve recommendations systematically understate their savings potential.
Align purchasing with formulary. Pharmacy purchasing and pharmacy and therapeutics (P&T) committee decisions should be synchronized. When the P&T committee approves a biosimilar conversion or a formulary addition, the purchasing team should have a clear protocol for updating contracted purchasing to align with the new formulary preference.
Report purchasing performance to leadership. Pharmacy spending should be a CFO-level metric, not just a departmental operational concern. Best-in-class programs produce monthly reporting that includes drug spend by category with trend lines, GPO compliance rates, 340B capture and compliance status, specialty drug spend by therapeutic area, and savings captured vs. opportunity identified.
Key Performance Indicators for Pharmacy Purchasing
Establishing the right KPIs is essential for building organizational accountability and demonstrating the financial impact of the purchasing program. The following metrics represent a best-practice pharmacy purchasing scorecard:
Financial KPIs
- Total drug spend vs. budget (by category, by site, by month)
- Drug cost per adjusted patient day (allows comparison across periods and benchmarking against peers)
- Savings captured vs. savings identified (measures execution efficiency)
- Invoice discrepancy recovery rate (dollars recovered as a percentage of discrepancies flagged)
- Contract leakage by supplier (dollar value of purchases made outside contracted pricing)
Compliance KPIs
- GPO compliance rate by category (percentage of purchases made at contracted pricing)
- 340B capture rate (percentage of eligible purchases using 340B pricing)
- Off-contract purchasing rate (percentage of orders placed outside the primary contracted channel)
Operational KPIs
- Recommendation review rate (percentage of optimization recommendations reviewed within target timeframe)
- Recommendation implementation rate (percentage of reviewed recommendations acted upon)
- Time from shortage identification to alternative sourced (measures shortage response efficiency)
- Inventory turnover rate by drug category
Forward-Looking KPIs
- Savings pipeline (total dollar value of identified but not yet implemented savings opportunities)
- Shortage risk exposure (number of high-risk NDCs currently in active use without secondary sourcing)
- Margin opportunity identified from reimbursement-aware recommendations (for institutions using margin-aware purchasing tools)
How to Reduce Drug Spend Without Impacting Patient Care
This is one of the most common questions pharmacy leaders face from clinical colleagues when initiating cost optimization programs. The concern is legitimate: the goal is never to compromise clinical outcomes in pursuit of financial savings. Best practices for maintaining this balance include:
- Focus first on true therapeutic equivalents: Generic substitution, equivalent NDC switching, and biosimilar adoption where clinical equivalence is established and accepted should be the foundation of the cost optimization program
- Involve clinical pharmacy in formulary decisions: Every NDC switch recommendation should pass through a clinical equivalence review before implementation
- Use shortage risk data to prevent substitution under duress: Proactive shortage management reduces the frequency of emergency substitutions made under supply pressure, which are the most clinically risky
- Separate purchasing optimization from utilization management: Cost optimization focuses on unit price; utilization management focuses on appropriate use. These are separate programs with different stakeholders and should not be conflated
Conclusion: Building a Future-Ready Pharmacy Purchasing Program
Hospital pharmacy purchasing is at an inflection point. The convergence of rising drug costs, specialty therapy growth, staff capacity constraints, ongoing shortage pressure, and emerging margin optimization opportunities has transformed purchasing from an administrative function into a strategic financial discipline.
The hospitals that will yield sustainable financial performance from their pharmacy programs are the ones that address all dimensions of the problem simultaneously:
- Cost reduction through GPO compliance, invoice auditing, NDC optimization, and biosimilar adoption
- Operational efficiency through technology that replaces manual processes with automated analytics and exception-based workflows
- Shortage risk management through predictive intelligence integrated directly into the purchasing workflow
- Margin optimization through reimbursement-aware purchasing decisions for specialty and infused medications
- Leadership visibility through financial reporting that positions pharmacy as a strategic CFO metric, not a departmental cost line
The technology to support all of this exists today. Purpose-built pharmacy purchasing analytics platforms have demonstrated consistent, documented ROI across facilities of all sizes – from critical access hospitals to large academic medical centers. The question for most organizations is not whether to invest in pharmacy purchasing optimization, but where to start and how quickly to build.
For organizations building or modernizing their pharmacy purchasing program, the practical starting point is a baseline assessment: an analysis of current purchasing data against contracted pricing that quantifies the scope of contract leakage, invoice discrepancies, and NDC optimization opportunities. Most reputable pharmacy analytics vendors can produce this assessment before a formal contract is in place, providing the business case data needed to secure organizational commitment.
The savings are there. The technology is proven. The financial pressure to act has never been higher.
About Bluesight
Bluesight provides pharmacy purchasing technology to more than 500 U.S. hospitals. CostCheck, Bluesight’s drug purchasing optimization platform, helps pharmacy teams identify and capture savings through invoice auditing, GPO compliance monitoring, NDC optimization, biosimilar analytics, and, importantly, margin-aware purchasing recommendations for specialty and infused medications. CostCheck integrates with ShortageCheck to provide real-time shortage risk intelligence alongside every savings recommendation.
Learn more about CostCheck → Request a savings analysis for your facility